Pentoxifylline decreases glycemia levels and TNF-alpha, iNOS and COX-2 expressions in diabetic rat pancreas

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-11

  Garcia, Francisca Adilfa O ^a   Pinto, Sofia F ^b   Cavalcante, Andrezza F ^b   Lucetti, Lívia T ^b   Menezes, Silvana M S ^a   Felipe, Cícero Francisco B ^b   Alves, Ana Paula N N ^a   Brito, Gerly Anne C ^a   Cerqueira, Gilberto S ^a   Viana, Glauce S B ^a,b  

^a Clinical Research Unity   (Brazil)

^b Estácio of Juazeiro do Norte   (Brazil)

Author keywords

Cytokines; Diabetes mellitus; Inflammation; Oxidative stress; Pentoxifylline

Indexed keywords

EID: 84904022791     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-283     Document Type: Article

References (37)

1. Badri S, Dashti-Khavidaki S, Lessan-Pezeshki M, Abdollahi M: A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. J Pharm Pharmaceut Sci 2011, 14: 128-137.
2. Borst SE: The role of TNF-alpha in insulin resistance. Endocrine 2004, 23: 177-182.
3. Coelho AMM, Kunitake TA, Machado MCC, Martins JO, Patzina RA, D'Albuquerque LA, Jukemura J: Is there a therapeutic window for pentoxifylline after the onset of acute pancreatitis. Acta Cir Bras 2012, 27: 487-493.
4. El-Bassossy HM, El-Moselhy MA, Mahmoud MF: Pentoxifylline alleviates vascular impairment in insulin resistance via TNF-alpha inhibition. Naunyn Schmiedebergs Arch Pharmacol 2011, 384: 277-285.
5. Flatt PR, Shibier O, Szecowka J: New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic β-cell. Diabetes Metab 1994, 20: 157-162.
6. Francés DE, Ingaramo PI, Ronco MT, Carnovale CE: Diabetes, an inflammatory process: oxidative stress and TNF-alpha involved in hepatic complications. J Biomed Sci Eng 2013, 6: 645-653.
7. Fujimoto M, Shimizu N, Ket K: A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 2005, 54: 1340-1348.
8. +concentration in an electrically excitable cell, the insulin-secreting pancreatic B-cell. J Biol Chem 1992, 267: 20713-20720.
9. Henquin JC, Meissner HP: Opposite effects of tolbutamide and diazoxide on 86 Rb + fluxes and membrane potential in pancreatic B-cells. Biochem Pharmacol 1982, 31: 1407-1415.
10. Hooper PL: Inflammation, heat shock proteins, and type 2 diabetes. Cell Stress Chaperones 2009, 14: 113-115.
11. Hotamisligil GS: Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999, 107: 119-125.
12. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259: 87-91.
13. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95: 2409-2415.
14. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95: 2111-2119.
15. Ling JJ, Sun YJ, Zhu DY, Chen Q, Han X: Potential role of NO in modulation of COX-2 expression and PGE2 production in pancreatic beta-cells. Acta Biochim Biophys (Shangai) 2005, 37: 139-146.
16. Luzi L, Pozza G: Gibenclamide: an old drug with a novel mechanism of action?Acta Diabetol 1997, 34: 239-244.
17. Marks V, Samols E: Diazoxide therapy of intractable hypoglycemia. Ann NY Acad Sci 1968, 150: 442-454.
18. Marton J, Farkas G, Takacs T, Nagy Z, Szasz Z, Varga J, Jarmay K, Balogh A, Lonovics J: Beneficial effects of pentoxifylline treatment of experimental acute pancreatitis in rats. Res Exp Med 1998, 197: 293-300.
19. McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G: The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008, 52: 454-463.
20. Moller DE: Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000, 11: 212-217.
21. Muhammed SJ, Lundquist I, Salehi A: Pancreatic beta-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes. Diabetes Obes Metab 2012, 14: 1010-1019.
22. Navarro-González JF, Jarque A, Muros M, Mora C, Garcia J: Tumor necrosis fator-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev 2009, 20: 165-173.
23. Persaud SJ, Burns CJ, Belin VD, Jones PM: Glucose-induced regulation of COX-2 expression in human islets of Langerhans. Diabetes 2004, 53: S190-192.
24. Plomgaard P, Nielsen AR, Fischer CP, Mortensen OH, Broholm C, Penkowa M, Krogh-Madsen R, Erikstrup C, Lindegaard B, Petersen AM, Taudorf S, Pedersen BK: Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia 2007, 50: 2562-2571.
25. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M: Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother 2005, 59: 302-306.
26. Renström E, Rorsman P: Intracellular tolbutamide stimulates calcium-dependent exocytosis in pancreatic beta-cells (Abstract). Diabetologia 1996, 39(1): A229.
27. Rodriguez-Morán M, Guerrero-Romero F: Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes. Curr Diabetes Rev 2008, 4: 55-62.
28. Sazhizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA: The expression of TNF-alpha by human muscle. Relationship to insulin resistance. J Clin Invest 1996, 97: 1111-1116.
29. Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, Steffes MW: Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 2011, 34: 960-967.
30. Sethi JK, Hotamisligil GS: The role of TNF-alpha in adipocyte metabolism. Semin Cell Dev Biol 1999, 10: 19-29.
31. Shafi T, Sozio SM, Plantinga LC, Jaar BG, Kim ET, Parekh RS, Steffes MW, Powe NR, Coresh J, Selvin E: Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care 2013, 36: 1522-1533.
32. Shan D, Wu HM, Yuan QY, Li J, Zhou RL, Liu GJ: Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev 2012. doi: 10. 1002/14651858.
33. Stosić-Grujicić SD, Maksimović DD, Stojković MB, Lukić ML: Pentoxifylline prevents autoimmune mediated inflammation in low dose streptozotocin induced diabetes. Dev Immunol 2001, 8: 213-221.
34. Stosić-Grujicić S, Maksimović D, Badovinac V, Samardzić T, Trajković V, Lukić M, Mostarica Stojković M: Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production. J Autoimmun 2001, 16: 47-58.
35. Trube G, Rorsman P, Ohno-Shozaku T: Opposite effects of tolbutamide and diazoxide on the ATP-sensitive potassium channel. Lancet 1986, 2: 493-499.
36. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005, 115: 1111-1119.
37. Zabel P, Schade FU, Schlaak M: Inhibition of endogenous TNF formation by pentoxifylline. Immunobiol 1993, 187: 447-463.